HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy
暂无分享,去创建一个
Michael J. Taylor | A. Gamst | C. Fennema-Notestine | I. Abramson | F. Vaida | C. Fennema-Notestine | T. Jernigan | A. Gamst | I. Grant | R. Heaton | D. Clifford | R. Ellis | I. Abramson | J. McCutchan | T. Marcotte | C. Marra | C. Marra | D. Simpson | S. Letendre | J. Wong | A. Collier | J. McArthur | S. Woods | D. Franklin | B. Gelman | S. Morgello | M. Taylor | F. Vaida | S. Morgello | I. Grant | M.J. Taylor | R.K. Heaton | D.B. Clifford | D.R. Franklin | S.P. Woods | C. Ake | R.J. Ellis | S.L. Letendre | T.D. Marcotte | J.H. Atkinson | M. Rivera-Mindt | O.R. Vigil | A.C. Collier | C.M. Marra | B.B. Gelman | J.C. McArthur | D.M. Simpson | J.A. McCutchan | T.L. Jernigan | J. Wong | D. M. Simpson | C. Ake | McCutchan Ja | J. Atkinson | M. Rivera-Mindt | I. Grant | O. Vigil | S. P. Woods | J. Mcarthur | J. Atkinson | Michael J. Taylor | Ofilio R. Vigil
[1] S. Lipton,et al. HIV neurocognitive disorders. , 2005 .
[2] K. Krause,et al. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases , 2005, Brain Research Reviews.
[3] I. Grant,et al. Interrater Reliability of Clinical Ratings and Neurocognitive Diagnoses in HIV , 2004, Journal of clinical and experimental neuropsychology.
[4] Carla J. Reicks,et al. The impact of HIV-associated neuropsychological impairment on everyday functioning , 2004, Journal of the International Neuropsychological Society.
[5] Susan Swindells,et al. The Neurology of AIDS , 1998 .
[6] P. Portegies,et al. Increasing Cerebrospinal Fluid Chemokine Concentrations Despite Undetectable Cerebrospinal Fluid HIV RNA in HIV‐1‐Infected Patients Receiving Antiretroviral Therapy , 2000, Journal of acquired immune deficiency syndromes.
[7] A. Monsch,et al. Neuropsychological studies of asymptomatic Human Immunodeficiency Virus-Type-1 infected individuals , 1995, Journal of the International Neuropsychological Society.
[8] F. Vaida,et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy , 2009, Neurology.
[9] I. Grant,et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders , 2004, Annals of neurology.
[10] Michael J. Taylor,et al. The HNRC 500-Neuropsychology of Hiv infection at different disease stages , 1995, Journal of the International Neuropsychological Society.
[11] R. Janssen,et al. Epidemiology of human immunodeficiency virus encephalopathy in the United States , 1992, Neurology.
[12] J. Becker,et al. Updated research nosology for HIV-associated neurocognitive disorders , 2007, Neurology.
[13] E. Rosenberg,et al. Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection , 2009, Neurology.
[14] John Chamberlain,et al. Disclosure , 2010, Annals of Internal Medicine.
[15] K. Marder,et al. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment , 1993, Neurology.
[16] P. Portegies,et al. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. , 2000 .
[17] Stuart A. Lipton,et al. Mechanisms of Neuroimmunity and Neurodegeneration Associated with HIV-1 Infection and AIDS , 2006, Journal of Neuroimmune Pharmacology.
[18] G. Chelune,et al. Neuropsychological and Personality Correlates of Patients’ Complaints of Disability , 1986 .
[19] P. Narciso,et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. , 1999, AIDS.
[20] I. Grant,et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome , 1997, Annals of neurology.
[21] P. Narciso,et al. Neuroactive Antiretroviral Drugs Do Not Influence Neurocognitive Performance in Less Advanced HIV-Infected Patients Responding to Highly Active Antiretroviral Therapy , 2006, Journal of acquired immune deficiency syndromes.
[22] Robert K Heaton,et al. Incident major depression does not affect neuropsychological functioning in HIV-infected men , 2006, Journal of the International Neuropsychological Society.
[23] I. Grant,et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. , 2008, Archives of neurology.
[24] K. Marder,et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. , 2007, Archives of neurology.
[25] Ronald A. Cohen,et al. Neurocognitive performance enhanced by highly active antiretroviral therapy in HIV-infected women , 2001, AIDS.
[26] A. Mocroft,et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. , 2000, Archives of internal medicine.
[27] J. Chmiel,et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients , 2002, AIDS.
[28] Maria Flora Salvatori,et al. Persistence of Neuropsychologic Deficits Despite Long-TermHighlyActiveAntiretroviralTherapyinPatients With HIV-Related Neurocognitive Impairment: Prevalence and Risk Factors , 2007, Journal of acquired immune deficiency syndromes.
[29] J. Rabkin,et al. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function , 1998, AIDS.
[30] Dianne Langford,et al. HIV and antiretroviral therapy in the brain: neuronal injury and repair , 2008, Nature Reviews Neuroscience.
[31] I Grant,et al. A multimodal assessment of driving performance in HIV infection , 2004, Neurology.
[32] D. Richman,et al. Resting cerebral blood flow , 2009, Neurology.